Multiple-drug-resistant enterococcal infections can be a serious problem in pediatric patients particularly concomitance with severe underlying diseases and lead to significant morbidity and mortality. The treatment options in children are limited compared with adults. We report a 3-year old-boy with acute myeloid leukemia (AML)-M7 and vancomycin-resistant enterococcus bacteremia successfully treated with daptomycin. Daptomycin may be an alternative therapy for VRE infections in children; more studies are needed for extended usage. 
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Daptomycin is a cyclic lipopeptide antimicrobial agent derived from Streptomyces roseosporus and it has in vitro bactericidal activity against grampositive pathogens. 2, 4 The clinical experience with daptomycin therapy in pediatric patients
Vancomycin-resistant Enterococcus bacteremia in a child with acute myeloid leukemia: Successful treatment with daptomycin
with VRE is limited. Moreover, drug dosage, safety and tolerability have not been definitely established in children. 2 We report our experience about treatment of a VRE bacteremia in a 3-yearold boy with acute myeloid leukemia (AML)-M7 and Down syndrome.
CASE REPORT
A 3-year-old patient with Down syndrome and AML-M7 was admitted to the Emergency Department due to fever at the fourth month of chemotherapy.
Medical history: When he was 23 months old, he was brought to the clinic with bone pain and inability to walk; he was diagnosed with pre B cell leukemia. St Jude's Total XV chemotherapy protocol was given for leukemia. The patient's foot pain repeated at the 28 weeks of chemotherapy; bone marrow aspiration revealed AML-M7. His treatment protocol was switched to AML BFM 2004. His past medical history was also remarkable for congenital heart disease (atrial septal defect and ventricular septal defect).
Physical examination: He was febrile (tympanic temperature was 38.5 °C), 2/6 systolic murmur was audible and hepatosplenomegaly was detected.
Laboratory data: Hemoglobin of 11.8 g/dL, platelet count of 190 × 10 3 /µL and a white blood cell count of 6700/µL (neutrophils 68%, lymphocytes and blasts 14%, monocytes 18%), with normal liver enzymes, kidney function tests and urinalysis. His erythrocyte sedimentation rate was 43 mm/h and C-reactive protein was 27.2 mg/dL (normal: 0-0,8 mg/dL).
The diagnosis of AML relapse was confirmed with bone marrow biopsy examination.
Day 1: The patient was hospitalized and meropenem was started due to neutropenic fever.
Day 7: Teicoplanin, amikacin were empirically added to the treatment because of the persistence of the fever. going on due to the clinical deterioration and prolonged fever. It was known that the patient was colonized with vancomycin-resistant Enterococcus faecium for the last eight months as detected in the surveillance cultures of stool. VRE was isolated from blood cultures which were taken from the central venous port and the peripheral vein on admission (VRE susceptibilities are shown in Table 1 ). Day 10: Linezolid (10 mg/kg/dose every 8 hours) was added and immunoglobulin M-enriched immunoglobulin (pentaglobulin 4.8 g/dose) was administered for four times.
Day 12: Ciprofloxacine was added for progression of pneumonia (Figure 1 ).
Day 13: VRE was still being isolated from blood cultures at the third day of linezolid treatment.
The central venous port was removed and replaced with a new vascular catheter on the 13 th day of therapy. Both procedures were also performed at the same time because of the necessity of vascular access. Trans-thoracic echocardiogram did not reveal valve vegetation.
D a y 2 1 : A m i k a c i n w a s s w i t c h e d w i t h gentamycin and repeat blood cultures continued to grow VRE.
Day 22: Daptomycin (8 mg/kg/day, a single dose) was added to linezolid at the 12 th day of therapy after consent of the parents and approval by The Ministry of Health of Turkey. Linezolid was continued after the beginning of daptomycin treatment.
Day 32: The blood culture of the patient was sterile. Daptomycin therapy was continued for 5-weeks during which the blood culture were negative ( Table 2 ). 
Abbreviations: MIC, minimum inhibitory concentration. *BioMerieux France.
e434 / Arch Argent Pediatr 2016;114(6):e432-e435 / Case report appeared as another alternative for the treatment of VRE infections in pediatric population in recent years. The effectiveness of the treatment was shown in several reports in children with meningitis, bacteremia, sepsis, endocarditis, and urinary tract infections caused by VRE. 2,9,10 A certain number of combination therapy including ampicilline, aminogycosides, ceftalorine, tigecyline, rifampicin, and doxycycline with daptomycine has been used succesfully for VRE infections in the literature 3 . In addition synergy between daptomycin and gentamicin, for highlevel gentamicin susceptible E. faecium has been already known 11 and it occured in our treatment. Therefore, we cannot generalize the potential benefit of multiantimicrobial usage.
Data are limited on the usage of daptomycin for pediatric patients. Also effective doses of daptomycin in children are different from adults and the optimal dosage is not well established. Daptomycin mostly binds a protein in circulation and is eliminated through kidneys. 2 Limited pharmacokinetic studies have manifested faster daptomycin clearance in children and it seems to have a shorter half-life in children aged 2-6 when compared to children aged 12-17. 10 Higher doses may be required in younger patients and the administration of 15 mg/kg/12 h was reported as a maximum dose in the literature in an infant. 2, 8 Our patient was treated at a dose of 8 mg/kg/ Serum CPK levels were in normal limits during the treatment. On 3th, 9th and 13th days after completion of daptomycin treatment the blood cultures were persistently negative. The previously planned FLAG IDA protocol for relapse AML was given. The patient died at the 77 th day of hospitalization due to pulmonary infection, bleeding and progression of AML. No specific microorganism was detected during the last episode of pulmonary infection and progression of disease.
DISCUSSION
Vancomycin-resistant enterococcal bacteremia has an unfavorable outcome in children. 5 While the various agents including quinupristindalfopristin, daptomycin, and tigecyline are being used for VRE infections in adults, limited treatment options are significant problems for children. The clinical cure rate of infections with antibiotic resistant gram-positive pathogens was reported as 69.7% in children treated with linezolid. 6 In another study by Grazzino et al., the clinical cure or improvement of VRE infections with linezolid was achieved in 66.7% of the pediatric patients. 7 However, linezolid has bacteriostatic activity to enterococcci and treatment failure may be seen despite susceptibility of VRE and removal of central venous port as in our patient. 8 Daptomycin has day and the use of daptomycin resulting in microbiological and clinical cure of infection without the observation of any side effects.
Several factors have related to an increase in the incidence of VRE infection, which may be attributed to several factors that increase the risk of infection, such as colonization of gastrointestinal tract, prior vancomycin or fluoroquinolone therapy, higher Acute Physiology and Chronic Health Evaluation II (APACHE) score and previous corticosteroid usage. Furthermore, in many reports, underlying hematologic malignancy, receiving chemotherapy, and high-grade bacteremia have been reported; the isolation of VRE from blood is significantly correlated with mortality. However these risk factors were showed in adult population and we have insufficient data in pediatric patients. 12, 13 The present case of persistent bloodstream VRE infection occurred in a boy with severe neutropenia following chemotherapy for relapsed AML-M7, and its clinical course shared similarities with those previously reported, particularly the poor outcome.
CONCLUSION
This report highlights the therapeutic approach of the persistent VRE bacteremia in a child with AML-M7 and Down syndrome, treated successfully with daptomycin. Despite susceptibility to linezolid, modification of antimicrobial therapy to daptomycin resolved the fever with favorable clinical and microbiological response in this case. We thought that more studies are needed to clarify the pharmacodynamics, pharmacokinetics, tolerability and toxicity of daptomycin in pediatric population, especially patients with underlying chronic diseases. n
